Dr. Finkelstein Discusses the Safety Profile of Radium-223

Video

For High-Definition, Click

Steven E. Finkelstein, MD, National Director of Translational Research, 21st Century Oncology, discusses the safety profile of radium-223 (Xofigo) to treat patients with bone metastases from castration-resistant prostate cancer (CRPC).

Finkelstein says the most common adverse reactions the patients experienced after receiving radium-223 were nausea, diarrhea, vomiting, and peripheral edema. Grade 3 and 4 adverse events were reported in 57% of radium-223-treated patients while 63% of placebo-treated patients reported such reactions, Finkelstein says, proving that radium-223 is a tolerable agent.

Anemia, lymphocytopenia, leukopenia, thrombocytopenia, and neutropenia were the most common hematologic laboratory abnormalities in radium-223-treated patients, Finkelstein says.

As radium-223 is a radionucleotide, Finkelstein says, radiation oncologists and nuclear medicine physicians both possess appropriate training to use the agent.

Finkelstein says that radium-223 was created in a specific way to become a practical option for community oncologists.

As the ALSYMPCA trial demonstrated a tolerable toxicity profile for radium-223, Finkelstein says, patients will be able to receive chemotherapy if radium-223 is ineffective.

Related Videos
Kara N. Maxwell, MD, PhD
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Rohan Garje, MD
Jeffrey P. Townsend, PhD
Rohan Garje, MD
Josep Maria Piulats Rodriguez, MD, PhD
Angela Jia, MD, PhD, of University Hospitals
Rohan Garje, MD, chief, Genitourinary Medical Oncology, Baptist Health Miami Cancer Institute
Kara N. Maxwell, MD, PhD
Mike Lattanzi, MD, medical oncologist, Texas Oncology